Hydralazine modifies Aβ fibril formation and prevents modification by lipids in vitro

Biochemistry

Volumn 49, Issue 49, 2010, Pages 10371-10380

  Maheshwari, Mukesh ^a   Roberts, Jessica K ^a   Desutter, Brent ^a   Duong, Karen T ^a   Tingling, Joseph ^a   Fawver, Janelle N ^a   Schall, Hayley E ^a   Kahle, Michael ^a   Murray, Ian V J ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4-HYDROXY-2-NONENAL; ALZHEIMER'S DISEASE PATHOLOGIES; BLOOD-BRAIN BARRIER; DISEASE PROGRESSION; DRUG DEVELOPMENT; DRUG DISCOVERY; FIBRIL FORMATION; FOOD AND DRUG ADMINISTRATION; HYDRALAZINE; HYDRAZIDE GROUPS; IN-VITRO; LIPID MODIFICATIONS; MISFOLDING; OXIDATIVE DAMAGE; POTENTIAL DRUG; PROTECTION ASSAY; PROTEIN MODIFICATIONS; SIDE EFFECT; SMOOTH MUSCLE RELAXANT; WESTERN BLOTTING;

ASTATINE; CHEMICAL MODIFICATION; DISEASES; DRUG INTERACTIONS; GLYCOPROTEINS; OLIGOMERS; PROTEINS; TRANSMISSION ELECTRON MICROSCOPY;

DRUG THERAPY;

4 HYDROXYNONENAL; AMYLOID BETA PROTEIN; HYDRALAZINE; LIPID; NIALAMIDE; OLIGOMER; PROTEINASE;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; DRUG ACTIVITY; DRUG EFFICACY; DRUG STRUCTURE; ELECTRON MICROSCOPY; FIBER; IN VITRO STUDY; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN FOLDING; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ALDEHYDES; AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; CELL DEATH; HUMANS; HYDRALAZINE; LIPID PEROXIDATION; LIPIDS; PC12 CELLS; PEPTIDE FRAGMENTS; PROTEIN FOLDING; RATS;

EID: 78650114682     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi101249p     Document Type: Article

References (85)

1. Selkoe, D. J. (2000) Toward a comprehensive theory for Alzheimer's disease-Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein Ann. N.Y. Acad. Sci. 924, 17-25
2. Hardy, J. and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics Science 297, 353
3. Markesbery, W. R. and Carney, J. M. (1999) Oxidative alterations in Alzheimer's disease Brain Pathol. 9, 133-146
4. Markesbery, W. R. (1997) Oxidative stress hypothesis in Alzheimer's disease Free Radical Biol. Med. 23, 134-147
5. Miranda, S., Opazo, C., Larrondo, L. F., Muñoz, F. J., Ruiz, F., Leighton, F., and Inestrosa, N. C. (2000) The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer's disease Prog. Neurobiol. 62, 633-648
6. Christen, Y (2000) Oxidative stress and Alzheimer disease Am. J. Clin. Nutr. 71, 621s-6629
7. Butterfield, D. A. and Lauderback, C. M. (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress Free Radical Biol. Med. 32, 1050-1060
8. Butterfield, D. A., Castegna, A., Lauderback, C. M., and Drake, J. (2002) Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death Neurobiol. Aging 23, 655-664
9. Selkoe, D. J. (2008) Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior Behav. Brain Res. 192, 106-113
10. 2 J. Biol. Chem. 277, 40302-40308
11. Butterfield, D. A. and Bush, A. I. (2004) Alzheimer's amyloid beta-peptide (1-42): Involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide Neurobiol. Aging 25, 563-568
12. Huang, X. D., Atwood, C. S., Hartshorn, M. A., Multhaup, G., Goldstein, L. E., Scarpa, R. C., Cuajungco, M. P., Gray, D. N., Lim, J., Moir, R. D., Tanzi, R. E., and Bush, A. I. (1999) The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction Biochemistry 38, 7609-7616 (Pubitemid 29289332)
13. Huang, X. D., Cuajungco, M. P., Atwood, C. S., Hartshorn, M. A., Tyndall, J. D. A., Hanson, G. R., Stokes, K. C., Leopold, M., Multhaup, G., Goldstein, L. E., Scarpa, R. C., Saunders, A. J., Lim, J, Moir, R. D., Glabe, C., Bowden, E. F., Masters, C. L., Fairlie, D. P., Tanzi, R. E., and Bush, A. I. (1999) Cu(II) potentiation of Alzheimer Abeta neurotoxicity-Correlation with cell-free hydrogen peroxide production and metal reduction J. Biol. Chem. 274, 37111-37116
14. Murray, I. V. J., Liu, L., Komatsu, H., Uryu, K., Xiao, G., Lawson, J. A., and Axelsen, P. H. (2007) Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins J. Biol. Chem. 282, 9335-9345
15. Nelson, T. J. and Alkon, D. L. (2005) Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide J. Biol. Chem. 280, 7377-7387
16. Masters, C. L., Simms, G, Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome Proc. Natl. Acad. Sci. U.S.A. 82, 4245-4249
17. Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin, Y. Y., Biemann, K., and Iqbal, K. (1993) Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease Arch. Biochem. Biophys. 301, 41-52
18. Smith, M. A., Harris, P. L. R., Sayre, L. M., and Perry, G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals Proc. Natl. Acad. Sci. U.S.A. 94, 9866-9868
19. Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., and Markesbery, W. R. (1998) Copper, iron and zinc in Alzheimer's disease senile plaques J. Neurol. Sci. 158, 47-52
20. Strausak, D., Mercer, J. F. B., Dieter, H. H., Stremmel, W., and Multhaup, G. (2001) Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases Brain. Res. Bull. 55, 175-185
21. Dong, J., Atwood, C. S., Anderson, V. E., Siedlak, S. L., Smith, M. A., Perry, G., and Carey, P. R. (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence Biochemistry 42, 2768-2773
22. Smith, D. G., Cappai, R., and Barnham, K. J. (2007) The redox chemistry of the Alzheimer's disease amyloid [beta] peptide Biochim. Biophys. Acta 1768, 1976-1990
23. Leskovjan, A. C., Lanzirotti, A., and Miller, L. M. (2009) Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease Neuroimage 47, 1215-1220
24. Rajendran, R., Minqin, R., Ynsa, M. D., Casadesus, G., Smith, M. A., Perry, G., Halliwell, B., and Watt, F. (2009) A novel approach to the identification and quantitative elemental analysis of amyloid deposits-Insights into the pathology of Alzheimer's disease Biochem. Biophys. Res. Commun. 382, 91-95
25. McLellan, M. E., Kajdasz, S. T., Hyman, B. T., and Bacskai, B. J. (2003) In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy J. Neurosci. 23, 2212-2217
26. Sayre, L. M., Perry, G., Harris, P. L. R., Liu, Y. H., Schubert, K. A., and Smith, M. A. (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: A central role for bound transition metals J. Neurochem. 74, 270-279
27. Burcham, P. C., Kerr, P. G., and Fontaine, F. R. (2000) The antihypertensive hydralazine is an efficient scavenger of acrolein Redox Rep. 5, 47-49
28. Burcham, P. C., Kaminskas, L. M., Fontaine, F. R., Petersen, D. R., and Pyke, S. M. (2002) Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products Toxicology 181-182, 229-236
29. Burcham, P. C., Fontaine, F. R., Kaminskas, L. M., Petersen, D. R., and Pyke, S. M. (2004) Protein adduct-trapping by hydrazinophthalazine drugs: Mechanisms of cytoprotection against acrolein-mediated toxicity Mol. Pharmacol. 65, 655-664
30. Kaminskas, L. M., Pyke, S. M., and Burcham, P. C. (2004) Strong protein adduct trapping accompanies abolition of acrolein-mediated hepatotoxicity by hydralazine in mice J. Pharmacol. Exp. Ther. 310, 1003-1010
31. Burcham, P. C. and Pyke, S. M. (2006) Hydralazine inhibits rapid acrolein-induced protein oligomerization: Role of aldehyde scavenging and adduct trapping in cross-link blocking and cytoprotection Mol. Pharmacol. 69, 1056-1065
32. Bieschke, J., Zhang, Q., Bosco, D. A., Lerner, R. A., Powers, E. T., Wentworth, P., and Kelly, J. W. (2006) Small molecule oxidation products trigger disease-associated protein misfolding Acc. Chem. Res. 39, 611-619
33. Kaminskas, L. M., Pyke, S. M., and Burcham, P. C. (2007) Michael addition of acrolein to lysinyl and N-terminal residues of a model peptide: Targets for cytoprotective hydrazino drugs Rapid Commun. Mass Spectrum 21, 1155-1164
34. Burcham, P. C., Kaminskas, L. M., Tan, D., and Pyke, S. M. (2008) Carbonyl-scavenging drugs & protection against carbonyl stress-associated cell injury Mini Rev. Med. Chem. 8, 319-330
35. Galvani, S., Coatrieux, C., Elbaz, M., Grazide, M. H., Thiers, J. C., Parini, A., Uchida, K., Kamar, N., Rostaing, L., Baltas, M., Salvayre, R., and Negre-Salvayre, A. (2008) Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives Free Radical Biol. Med. 45, 1457-1467
36. Kishi., H., Kishi, T., and Folkers, K. (1975) Bioenergetics in clinical medicine. III. Inhibition of coenzyme Q10-enzymes by clinically used anti-hypertensive drugs Res. Commun. Chem. Pathol. Pharmacol. 12, 533-540
37. Leiro, J. M., Alvarez, E., Arranz, J. A., Cano, E., and Orallo, F. (2004) Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages Int. Immunopharmacol. 4, 162-177
38. Daiber, A., Oelze, M., Coldewey, M., Kaiser, K., Huth, K., Schildknecht, S., Bachschmid, M., Nazirisadeh, Y., Ullrich, V., Mulsch, A., Munzel, T., and Tsilimingas, N. (2005) Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure Biochem. Biophys. Res. Commun. 338, 1865-1674
39. Liu-Snyder, P., Borgens, R. B., and Shi, R. (2006) Hydralazine rescues PC12 cells from acrolein-mediated death J. Neurol. Res. 84, 219-227
40. Vindis, C., Escargueil-Blanc, I., Elbaz, M., Marcheix, B., Grazide, M. H., Uchida, K., Salvayre, R., and Negre-Salvayre, A. (2006) Desensitization of platelet-derived growth factor receptor-β by oxidized lipids in vascular cells and atherosclerotic lesions: Prevention by aldehyde scavengers Circ. Res. 98, 785-792
41. Mehta, R., Wong, L., and O'Brien, P. J. (2009) Cytoprotective mechanisms of carbonyl scavenging drugs in isolated rat hepatocytes Chem.-Biol. Interact. 178, 317-323
42. Hamann, K. and Shi, R. (2009) Acrolein scavenging: A potential novel mechanism of attenuating oxidative stress following spinal cord injury J. Neurochem. 111, 1348-1356
43. Zheng, J. and Bizzozero, O. A. (2010) Traditional reactive carbonyl scavengers do not prevent the carbonylation of brain proteins induced by acute glutathione depletion Free Radical Res. 44, 258-266
44. Reece, P. (1981) Hydralazine and related compounds: Chemistry, metabolism, and mode of action Med. Res. Rev. 1, 73-96
45. Wang, J., Ho, L., Chen, L., Zhao, Z., Zhao, W., Qian, X., Humala, N., Seror, I., Bartholomew, S., Rosendorff, C., and Pasinetti, G. M. (2007) Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease J. Clin. Invest. 117, 3393-3402
46. Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C., Necula, M., Margol, L., Wu, J., Breydo, L., Thompson, J., Rasool, S., Gurlo, T., Butler, P., and Glabe, C. G. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers Mol. Neurodegener. 2, 18
47. Kayed, R. and Glabe, C. G. (2006) Conformation-dependent anti-amyloid oligomer antibodies, in Methods in Enzymology: Amyloid, Prions, and Other Protein Aggregates, Part C (Kheterpal, I. and Wetzel, R., Eds.) Academic Press, New York.
48. Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., De Felice, F. G., Krafft, G. A., and Klein, W. L. (2007) Monoclonal antibodies that target pathological assemblies of Abeta J. Neurochem. 100, 23-35
49. Boye-Harnasch, M. and Cullin, C. (2006) A novel in vitro filter trap assay identifies tannic acid as an amyloid aggregation inducer for HET-s J. Biotechnol. 125, 222-230
50. Wanker, E. E., Scherzinger, E., Heiser, V., Sittler, A., Eickhoff, H., and Lehrach, H. (1999) Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates Methods Enzymol. 309, 375-386
51. Chang, E. and Kuret, J. (2008) Detection and quantification of tau aggregation using a membrane filter assay Anal. Biochem. 373, 330-336
52. Giasson, B. I., Murray, I. V. J., Trojanowski, J. Q., and Lee, V. M. Y. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly J. Biol. Chem. 276, 2380-2386
53. Zhang, R., Hu, X., Khant, H., Ludtke, S. J., Chiu, W., Schmid, M. F., Frieden, C., and Lee, J. M. (2009) Interprotofilament interactions between Alzheimer's A1-42 peptides in amyloid fibrils revealed by cryoEM Proc. Natl. Acad. Sci. U.S.A. 106, 4653-4658
54. Dolphin, G. T., Ouberai, M., Dumy, P., and Garcia, J. (2007) Designed amyloid β peptide fibril-A tool for high-throughput screening of fibril inhibitors ChemMedChem 2, 1613-1623
55. Necula, M., Kayed, R., Milton, S., and Glabe, C. G. (2007) Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct J. Biol. Chem. 282, 10311-10324
56. Kalyanaraman, B. and Sinha, B. K. (1985) Free radical-mediated activation of hydrazine derivatives Environ. Health Perspect. 64, 179-184
57. Reilly, C. A. and Aust, S. D. (1997) Peroxidase substrates stimulate the oxidation of hydralazine to metabolites which cause single-strand breaks in DNA Chem. Res. Toxicol. 10, 328-334
58. LaCagnin, L. B., Colby, H. D., Dalal, N. S., and O'Donnell, J. P. (1987) Metabolic activation of hydralazine by rat liver microsomes Biochem. Pharmacol. 36, 2667-2672
59. Timperio, A. M., Rinalducci, S., and Zolla, L. (2005) Hydrazide derivatives produce active oxygen species as hydrazine Bioorg. Chem. 33, 459-469
60. Halliwell, B. and Gutteridge, J. M. C. (2000) Free Radicals in Biology and Medicine, 3 rd ed., Academic Press, Oxford.
61. Rugale, C. M., Delbosc, S. P., Mimran, A. M., and Jover, B. P. (2007) Simvastatin reverses target organ damage and oxidative stress in angiotensin II hypertension: Comparison with apocynin, tempol, and hydralazine J. Cardiovasc. Pharmacol. 50, 293-298
62. Nangaku, M., Miyata, T., Sada, T., Mizuno, M., Inagi, R., Ueda, Y., Ishikawa, N., Yuzawa, H., Koike, H., van Ypersele de Strihou, C., and Kurokawa, K. (2003) Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model J. Am. Soc. Nephrol. 14, 1212-1222
63. Araki, S., Hirooka, Y., Kishi, T., Yasukawa, K., Utsumi, H., and Sunagawa, K. (2009) Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method Hypertens. Res. 32, 1091-1096
64. Yoshida, S., Hashimoto, T., Kihara, M., Imai, N., Yasuzaki, H., Nomura, K., Kiuchi, Y., Tamura, K., Ishigami, T., Hirawa, N., Toya, Y., Kitamura, H., and Umemura, S. (2009) Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy Nephron Exp. Nephrol. 111, e20-e30
65. Nichols, M. R., Moss, M. A., Reed, D. K., Lin, W. L., Mukhopadhyay, R., Hoh, J. H., and Rosenberry, T. L. (2002) Growth of β-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy Biochemistry 41, 6115-6127
66. de Groot, N. S., Aviles, F. X., Vendrell, J., and Ventura, S. (2006) Mutagenesis of the central hydrophobic cluster in Abeta42 Alzheimer's peptide. Side-chain properties correlate with aggregation propensities FEBS J. 273, 658-668
67. Luhrs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Doeli, H., Schubert, D., and Riek, R. (2005) 3D structure of Alzheimer's amyloid-beta(1-42) fibrils Proc. Natl. Acad. Sci. U.S.A. 102, 17342-17347
68. Petkova, A. T., Yau, W. M., and Tycko, R. (2005) Experimental constraints on quaternary structure in Alzheimer's β-amyloid fibrils Biochemistry 45, 498-512
69. Sato, T., Kienlen-Campard, P., Ahmed, M., Liu, W., Li, H., Elliott, J. I., Aimoto, S., Constantinescu, S. N., Octave, J. N., and Smith, S. O. (2006) Inhibitors of amyloid toxicity based on β-sheet packing of Aβ40 and Aβ42 Biochemistry 45, 5503-5516
70. Ma, B. and Nussinov, R. (2006) Simulations as analytical tools to understand protein aggregation and predict amyloid conformation Curr. Opin. Chem. Biol. 10, 445-452
71. Kheterpal, I., Williams, A., Murphy, C., Bledsoe, B., and Wetzel, R. (2001) Structural features of the A beta amyloid fibril elucidated by limited proteolysis Biochemistry 40, 11757-11767
72. George, A. R. and Howlett, D. R. (1999) Computationally derived structural models of the beta-amyloid found in Alzheimer's disease plaques and the interaction with possible aggregation inhibitors Biopolymers 50, 733-741
73. Stopa, B., Piekarska, B., Konieczny, L., Rybarska, J., Spolnik, P., Zemanek, G., Roterman, I., and Krol, M. (2003) The structure and protein binding of amyloid-specific dye reagents Acta Biochem. Pol. 50, 1213-1227
74. Porat, Y., Abramowitz, A., and Gazit, E. (2006) Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism Chem. Biol. Drug Des. 67, 27-37
75. Gazit, E. (2002) A possible role for pi-stacking in the self-assembly of amyloid fibrils FASEB J. 16, 77-83
76. Pitt, J., Roth, W., Lacor, P., Smith, A. B., III, Blankenship, M., Velasco, P., De Felice, F., Breslin, P., and Klein, W. L. (2009) Alzheimer's-associated Aβ oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal Toxicol. Appl. Pharmacol. 240, 189-197
77. Hamaguchi, T., Ono, K., Murase, A., and Yamada, M. (2009) Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-β aggregation pathway Am. J. Pathol. 175, 2557-2565
78. Cherny, R. A., Legg, J. T., McLean, C. A., Fairlie, D. P., Huang, X. D., Atwood, C. S., Beyreuther, K., Tanzi, R. E., Masters, C. L., and Bush, A. I. (1999) Aqueous dissolution of Alzheimer's disease A beta amyloid deposits by biometal depletion J. Biol. Chem. 274, 23223-23228
79. Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y. S., Huang, X. D., Goldstein, L. E., Moir, R. D., Lim, J. T., Beyreuther, K., Zheng, H., Tanzi, R. E., Masters, C. L., and Bush, A. I. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice Neuron 30, 665-676
80. Bush, A. I. (2003) The metallobiology of Alzheimer's disease Trends Neurosci. 26, 207-214
81. Bush, A. I. and Tanzi, R. E. (2008) Therapeutics for Alzheimer's disease based on the metal hypothesis Neurotherapeutics 5, 421-432
82. Weglicki, W. B. and Mak, I. T. (1992) Antioxidant drug mechanisms: Transition metal-binding and vasodilation Mol. Cell. Biochem. 118, 105-111
83. Al-Falahi, H., May, P. M., Roe, A. M., Slater, R. A., Trolt, W. J., and Williams, D. R. (1984) Metal binding by pharmaceuticals. Part 4. A comparative investigation of the interaction of metal ions with hydralazine, prizidilol and related compounds Agents Actions 14, 113-120
84. Takeda, S., Sato, N., Takeuchi, D., Kurinami, H., Shinohara, M., Niisato, K., Kano, M., Ogihara, T., Rakugi, H., and Morishita, R. (2009) Angiotensin receptor blocker prevented β-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling Hypertension 54, 1345-1352
85. Gerber, J. G., Freed, C. R., and Nies, A. S. (1980) Antihypertensive pharmacology West. J. Med. 132, 430-439